drugset / Trial / NCT00977145
Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma
NaSingle-groupOpen-labelTreatment
Summary
The goals of this study are to evaluate 1) the safety of administration of intratumoral interferon gamma with a peptide-based vaccine, in patients with melanoma and 2) the biological effects of the vaccine. These include an examination of changes within the tumor following vaccination and the evaluation of T cell responses to the vaccine both in the blood and at the sight of tumor.
Timeline
- Start
- 2009-11
- Primary completion
- 2012-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MELITAC 12.1 | Vaccine | 100 ug | Subcutaneous |
| Subject | MELITAC 12.1 | Vaccine | 200 ug | Subcutaneous |
| Subject | interferon gamma | Protein / enzyme biologic | 2e+06 iu | Other |